Development of Oncolytic Adenovirus Formulation with a Stealth Effect – Expansion from Local to Systemic Administration

December 22(Fri), 2017

Toshiyoshi Fujiwara, Professor at the Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Hiroshi Tazawa, Associate Professor, and Shinji Kuroda, Assistant Professor at the Center for Innovative Clinical Medicine, Okayama University Hospital and their research group successfully developed an oncolytic adenovirus formulation with a stealth effect that can be used for systemic administration by combining the oncolytic adenovirus with nanotechnology. Oncolytic adenovirus had been used only for local administration until now. This research success was published in the electronic version of the British science magazine “Scientific Reports” (Nature Publishing Group) on October 26, 2017.


The effectiveness of the local administration of oncolytic adenovirus has been verified in clinical trials in Japan. Further clinical development of an oncolytic adenovirus formulation that can be used for systemic administration will be helpful for the treatment of progressive cancers or cancers in areas that are hard to treat locally. The new formulation is expected to lead to further applications.


Article Information

DOI: 10.1038/s41598-017-14717-x

Authors: Katsuyuki AoyamaShinji KurodaToshiaki MorihiroNobuhiko KanayaTetsushi KubotaYoshihiko KakiuchiSatoru KikuchiMasahiko ishizakiShunsuke KagawaHiroshi Tazawa & Toshiyoshi Fujiwara

Journal: Scientific Reports 

Title: Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system.

Year of Publication: 2017


Okayama University Silicon Valley Office (OUSVO)

Contact: Mototaka Senda, Ph.D.

Phone:    (1)510-894-3067



Oncolytic Adenovirus Formulation, progressive cancers, cancers

Back to List